Vociprotafib

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H27ClN6O2S
Molecular Weight	450.985
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1OCC2(CCN(CC2)C3=NC(C)=C(SC4=CC=NC(N)=C4Cl)N=C3CO)[C@@H]1N

InChI

InChIKey=HISJAYUQVHMWTA-BLLLJJGKSA-N

InChI=1S/C20H27ClN6O2S/c1-11-19(30-14-3-6-24-17(23)15(14)21)26-13(9-28)18(25-11)27-7-4-20(5-8-27)10-29-12(2)16(20)22/h3,6,12,16,28H,4-5,7-10,22H2,1-2H3,(H2,23,24)/t12-,16+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H27ClN6O2S
Molecular Weight	450.985
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

C_max

Value	Dose	Co-administered	Analyte	Population
984 nM EXPERIMENT https://www.ejcancer.com/article/S0959-8049(20)31089-3/abstract	140 mg 2 times / week multiple, oral dose: 140 mg route of administration: Oral experiment type: MULTIPLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
242 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03989115	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
286 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03989115	100 mg 2 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
55298 nM × h EXPERIMENT https://www.ejcancer.com/article/S0959-8049(20)31089-3/abstract	140 mg 2 times / week multiple, oral dose: 140 mg route of administration: Oral experiment type: MULTIPLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3360 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03989115	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4230 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03989115	100 mg 2 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
26 h EXPERIMENT https://www.ejcancer.com/article/S0959-8049(20)31089-3/abstract	140 mg 2 times / week multiple, oral dose: 140 mg route of administration: Oral experiment type: MULTIPLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.1 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03989115	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
24.6 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03989115	100 mg 2 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: COBIMETINIB	COBIMETINIB	VOCIPROTAFIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
40% EXPERIMENT https://s3-us-west-2.amazonaws.com/rvmdpubs.revmed.com/2020/ED03+Discovery+and+development+of+allosteric+inhibitors+of+SHP2.pdf	unknown, oral		VOCIPROTAFIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Substance Class	Chemical Created by `admin` on `Wed Apr 02 03:59:05 GMT 2025` Edited by `admin` on `Wed Apr 02 03:59:05 GMT 2025`
Record UNII	C4YBF9170L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Vociprotafib

Official Name

English

RMC-4630

Preferred Name

English

RMC-0694630

Code

English

PTPN11 inhibitor RMC-4630

Common Name

English

RMC4630

Code

English

6-[(2-Amino-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-methyl-2-pyrazinemethanol

Systematic Name

English

2-Pyrazinemethanol, 6-[(2-amino-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-methyl-

Systematic Name

English

RMC 4630 [WHO-DD]

Common Name

English

SAR442720

Code

English

vociprotafib [INN]

Common Name

English

SAR-442720

Code

English

VOCIPROTAFIB [USAN]

Common Name

English

Code System Code Type Description

INN

12270